SG
BOLT icon

StoneX Group’s Bolt Biotherapeutics BOLT Stock Holding History

StoneX Group’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-777
Closed -$6.21K – 892
2025
Q1 		$6.21K Buy
+777
New +$7.47K ﹤0.01% 830

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

StoneX Group's BOLT Position: Q2 2025 in Review

StoneX Group sold out of Bolt Biotherapeutics (BOLT) in Q2 2025, closing a stake of 777 shares — an estimated $6.21K sold.

StoneX Group first reported a position in BOLT in Q1 2025 and held it in 1 quarter. The position peaked at $6.21K in Q1 2025. 25 funds tracked by Wall St. Rank hold BOLT as of Q2 2025.

  • StoneX Group reported no remaining Bolt Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • StoneX Group sold 777 Bolt Biotherapeutics shares in Q2 2025, an estimated $6.21K.
  • StoneX Group first reported a position in Bolt Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • StoneX Group's Bolt Biotherapeutics position peaked at $6.21K in Q1 2025.
  • 25 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2025.

Based on StoneX Group's 13F filing for Q2 2025, filed 13 Aug 2025.